Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug

References

• Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013;15:340.
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305.
   PubMed Web of Science ®Google Scholar
• Judge P, Haynes R, Landray MJ, et al. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant. 2015;30:738–743.
   PubMed Web of Science ®Google Scholar
• Hirsch JR, Meyer M, Forssmann WG. ANP and urodilatin: who is who in the kidney. Eur J Med Res. 2006;11:447–454.
   PubMed Web of Science ®Google Scholar
• Burnett JC Jr., Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145–1147.
   PubMed Web of Science ®Google Scholar
• Mukoyama M, Nakao K, Saito Y, et al. Imura H Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med. 1990;323:757–758.
   PubMed Web of Science ®Google Scholar
• Potter LR. Natriuretic peptide metabolism, clearance and degradation. Febs J. 2011;278:1808–1817.
   PubMed Web of Science ®Google Scholar
• Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014;176:630–639.
   PubMed Web of Science ®Google Scholar
• Scotland RS, Ahluwalia A, Hobbs AJ. C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther. 2005;105:85–93.
   PubMed Web of Science ®Google Scholar
• Potter LR, Yoder AR, Flora DR, et al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;191:341–366.
   PubMedGoogle Scholar
• Nawarskas JJ, Anderson JR. Omapatrilat: a unique new agent for the treatment of cardiovascular disease. Heart Dis. 2000;2:266–274.
   PubMedGoogle Scholar
• Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103–111.
   PubMed Web of Science ®Google Scholar
• Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008;153:947–955.
   PubMed Web of Science ®Google Scholar
• Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2004;1:45–50.
   PubMedGoogle Scholar
• Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10:607–613.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The international ecadotril multi-centre dose-ranging study investigators. Lancet. 1998;351:1657–1658.
   PubMed Web of Science ®Google Scholar
• Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2:663–670.
   PubMed Web of Science ®Google Scholar
• Buggey J, Mentz RJ, DeVore AD, et al. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. J Card Fail. 2015;21:741–750.
   PubMed Web of Science ®Google Scholar
• Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130:57–77.
   PubMed Web of Science ®Google Scholar
• Pham AQ, Patel Y, Gallagher B. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block? J Pharm Pract. 2015;28:137–145.
   PubMedGoogle Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401–414.
   PubMed Web of Science ®Google Scholar
• Kobalava Z, Kotovskaya Y, Averkov O, et al. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. Cardiovasc Ther. 2016;34:191–198.
   PubMed Web of Science ®Google Scholar
• van den Heuvel TW, Cohen AF, Rissmann R. European drug market entries 2015 with new mechanisms of action. Clin Med (Lond). 2016;16:475–480.
   PubMed Web of Science ®Google Scholar
• Akahori M, Ayalasomayajula S, Langenickel T, et al. Pharmacokinetics after single ascending dose, food effect, and safety of sacubitril/valsartan (LCZ696), an angiotensin receptor and neprilysin inhibitor, in healthy Japanese subjects. Eur J Drug Metab Pharmacokinet. 2016.[Epub ahead of print]. PubMed PMID: 27324506.
   PubMedGoogle Scholar
• Han Y, Ayalasomayajula S, Pan W, et al. Pharmacokinetics, safety and tolerability of sacubitril/valsartan (LCZ696) after single-dose administration in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2017;42:109–116.
   Web of Science ®Google Scholar
• Flarakos J, Du Y, Bedman T, et al. Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. Xenobiotica. 2016;46:986–1000.
   PubMed Web of Science ®Google Scholar
• Hsiao HL, Langenickel TH, Greeley M, et al. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Clin Pharmacol Drug Dev. 2015;4:407–417.
   PubMed Web of Science ®Google Scholar
• Gan L, Jiang X, Mendonza A, et al. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Clin Pharmacol Drug Dev. 2016;5:27–39.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula S, Han Y, Langenickel T, et al. In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). J Clin Pharm Ther. 2016;41:424–431.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula S, Pan W, Han Y, et al.Assessment of drug-drug interaction potential between atorvastatin and LCZ696, A novel angiotensin receptor neprilysin inhibitor, in healthy Chinese male subjects. Eur J Drug Metab Pharmacokinet. 2017;42:309-318.
   Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation. 2016;133:e38–360. Epub 2015/12/18.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–619.
   PubMed Web of Science ®Google Scholar
• Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide study group. N Engl J Med. 2000;343:246–253.
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. Jama. 2002;287:1531–1540.
   PubMed Web of Science ®Google Scholar
• Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798–803.
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. Jama. 2005;293:1900–1905.
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.
   PubMed Web of Science ®Google Scholar
• Fala L. Entresto (Sacubitril/Valsartan): first-in-class angiotensin receptor neprilysin Inhibitor FDA approved for Heart Failure. Am Health Drug Benefits. 2016;9:78–82.
   PubMedGoogle Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282–93. Epub 2016/05/22.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;2016(18):891–975.
   Web of Science ®Google Scholar
• EMEA. European public assessment report (EPAR) for Entresto 2015 [cited 2016 Nov 12]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004062/human_med_001929.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Claggett B, Packer M, McMurray JJ, et al. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. N Engl J Med. 2015;373:2289–2290.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–1395.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–1266.
   PubMed Web of Science ®Google Scholar
• Wang TD, Tan RS, Lee HY, et al. Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension. Hypertension. 2017;69:32–41.
   PubMed Web of Science ®Google Scholar
• Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698–705.
   PubMed Web of Science ®Google Scholar
• Ito S, Satoh M, Tamaki Y, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015;38:269–275.
   PubMed Web of Science ®Google Scholar
• Supasyndh O, Sun N, Kario K, et al. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension. Hypertens Res. 2016. Epub 2016/11/18. doi: 10.1038/hr.2016.151.
   PubMedGoogle Scholar
• Benigni A, Zoja C, Zatelli C, et al. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int. 2004;66:1959–1965.
   PubMed Web of Science ®Google Scholar
• Davis BJ, Johnston CI, Burrell LM, et al. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia. 2003;46:961–971.
   PubMed Web of Science ®Google Scholar
• Cataliotti A, Boerrigter G, Chen HH, et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation. 2002;105:639–644.
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615–620.
   PubMed Web of Science ®Google Scholar
• Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–926.
   PubMed Web of Science ®Google Scholar
• Lipkin GW, Dawnay AB, Harwood SM, et al. Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure. Kidney Int. 1997;52:792–801.
   PubMed Web of Science ®Google Scholar
• Seymour AA, Asaad MM, Lanoce VM, et al. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther. 1993;266:872–883.
   PubMed Web of Science ®Google Scholar
• Kusaka H, Sueta D, Koibuchi N, et al. LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone. Am J Hypertens. 2015;28:1409–1417.
   PubMed Web of Science ®Google Scholar
• Wang BH, Von Lueder TG, Kompa AR, et al. Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. Int J Cardiol. 2015;186:104–105.
   PubMed Web of Science ®Google Scholar
• Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17:510–517.
   PubMed Web of Science ®Google Scholar
• Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18:1193–1202.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Langenickel TH, Jordaan P, et al. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. Eur J Clin Pharmacol. 2016;72:1065–1073.
   PubMed Web of Science ®Google Scholar
• UK HARP-III Collaborative Group.Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: united Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data. Nephrol Dial Transplant. 2016. pii: gfw321. [Epub ahead of print] PubMed PMID: 27646835.
   Google Scholar
• Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. Kidney Int. 2007;72:208–212.
   PubMed Web of Science ®Google Scholar
• Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936–946.
   PubMed Web of Science ®Google Scholar
• Saran R, Li Y, Robinson B, et al. US renal data system 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67(Svii):S1–305.
   Google Scholar
• Meyrier A. Nephrosclerosis: a term in quest of a disease. Nephron. 2015;129:276–282.
   PubMed Web of Science ®Google Scholar